Below are a few excerpts from the Internet and documents from...

Below are a few excerpts from the Internet and documents from the Company:

"Monoclonal antibodies are a workhorse of modern medicine with global sales of >$US82bn pa. However, monoclonal antibodies, renowned for their exquisite targeting ability, are generally too large to make it through the cell membrane to attack intracellular targets of therapeutic interest."

"Deoxymab 3E10 is a notable exception. Deoxymab’s ability to make it through the cell membrane opens opportunities for bi-specific antibodies that target intracellular targets..... Deoxymab is one of the rare antibodies that are cell-penetrating, allowing it to go after DDR via intra-cellular targets."

"Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapeutic drug, these conjugates are believed to be more efficient and effective in the treatment of a disease. The ADC market is still in its infancy."

"Patrys can link PAT-DX1 to nanoparticles loaded with standard chemotherapeutic agents or other drugs for the targeted delivery of anticancer medications and imaging agents."

"Gaining rights to early-stage assets gives the licensee more flexibility to shape its development. Furthermore, early-stage assets often comprise of "platforms" which could deliver multiple new drugs. Increased competition for early stage assets appears to be driving total deal values higher in this sector."

"With a wide range of potential applications for Deoxymab technology, Patrys is open to discussions on how best to exploit the platform’s multiple uses."

Again, Patrys is now onto something big and in a very good position to engage in detailed discussions with prospective partners, and it must be the case that there is significant interest in PAT-DX1 from global pharma giants.